Title | Authors | Journal | Date | Link |
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma | Leypoldt LB et al. | J Clin Oncol. | 1 January 2024 | |
Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity | Samikshya Santosh Nirmala et al. | Front Immunology. | 12 January 2024 | |
Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T-cell function while promoting a senescence-associated phenotype | Russell Towers et al. | Cancer Immunol Immunothery. | 17 January 2024 | |
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial | Platzbecker U et al. | Lancet. | 20 January 2024 | |
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL | Stelljes M et al. | J Clin Oncol. | 20 January 2024 | |
CAR T-cell therapy in multiple myeloma: mission accomplished? | Rasche L et al. | Blood. | 25 January 2024 | |
Activation of recombinases at specific DNA loci by zinc-finger domain insertions | Mukhametzyanova L et al. | Nat Biotechnol. | 31 January 2024 | |
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation | Bischof L et al. | Leukemia. | January 2024 | |
CAR T cell therapy in multiple myeloma, where are we now and where are we heading for? | Fischer L et al. | Eur J Haematol. | January 2024 | |
Isolation, Ex Vivo Expansion, and Lentiviral Transduction of Alveolar Macrophages | Busch CJ-L et al. | Methods Mol Biol. | January 2024 | |
Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6 | Maximilian Walther et al. | Eur J Pharm Biopharm. | 22 February 2024 | |
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation | Jiri Eitle et al. | J Immunother Cancer. | 27 February 2024 | |
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia | Kovtun I et al. | Leukemia. | February 2024 | |
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study | Weller JF et al. | Haematologica. | February 2024 | |
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT | Rovó A et al. | Am J Hematol. | February 2024 | |
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients | Mai EK et al. | Leukemia. | March 2024 | |
Microcavity well-plate for automated parallel bioelectronic analysis of 3D cell cultures | Franziska D Zitzmann et al. | Biosens Bioelectron. | 15 April 2024 | |
Spray-drying of PEI-/PPI-based nanoparticles for DNA or siRNA delivery | Sandra Noske et al. | Eur J Pharm Biopharm. | June 2024 | |
Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells | Renner A et al. | Gene Ther. | July 2024 | |
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study | Niederwieser D et al. | Haematologica. | 8 August 2024 | |
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features | Sierro-Martínez B et al. | Cell Oncol (Dordr). | 27 August 2024 | |
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma | Rade M et al. | Nat Cancer. | 5 September 2024 | |
Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells | Staudt S et al. | bioRxiv. | 13 September 2024 | |
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma | Kirchberg J et al. | Clin Lymphoma Myeloma Leuk. | 24 September 2024 | |
Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review | Fischer S et al. | Support Care Cancer. | 25 September 2024 | |
RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma | Saleh HA et al. | Cancer Gene Ther. | September 2024 | |
Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies | Araujo AE et al. | Hum Gene Ther. | September 2024 | |
The best of both worlds: AAV-mediated gene transfer empowered by LNP delivery of Sleeping Beauty transposase for durable transgene expression in vivo | Nicolás Sandoval-Villegas et al. | Mol Ther. | 2 October 2024 | |
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses | von Jan J et al. | Blood. | 10 October 2024 | |
Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma. | Fandrei D et al. | Blood Cancer Discov. | 23 October 2024 | |
Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma | Dominik Zolnowski et al. | Springer Nature Link. | 29 October 2024 | |
Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection | Navarro S et al. | Mol Ther. | 12 November 2024 | |
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries | Récher C et al. | Am J Hematol. | 18 November 2024 | |
Cellular Therapies for Multiple Myeloma: Engineering Hope | Sarah Vera-Cruz et al. | Cancers. | 19 November 2024 | |
Single-Cell RNA Sequencing Reveals Repair Features of Human Umbilical Cord Mesenchymal Stromal Cells | Cyr-Depauw C et al. | Am J Respir Crit Care Med. | 25 November 2024 | |
Recent advances in development and delivery of non-viral nucleic acid therapeutics for brain tumor therapy. | Kögel D et al. | Pharmacol Ther. | 26 November 2024 | |
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function | Barden M et al. | J Immunother Cancer. | 2 December 2024 | |
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy | Merz M et al. | Blood Cancer. | 05 December 2024 | |
DNA binding and transposition activity of the Sleeping Beauty transposase: role of structural stability of the primary DNA-binding domain. | Ranjan VV et al. | Nucleic Acids Res. | 9 December 2024 | |
Isolation, Ex Vivo Expansion, and Lentiviral Transduction of Alveolar Macrophages | Busch CJL et al. | Methods Mol Biol. | 2024 |
What lies behind SaxoCell’s research and development projects? What are the scientists working on, and what new treatment options could emerge from their work? Six new short videos offer exciting insights into the cluster’s current translational projects.
